Back to top
more

QIAGEN (QGEN)

(Delayed Data from NYSE)

$46.36 USD

46.36
946,981

+0.79 (1.73%)

Updated Sep 13, 2024 04:00 PM ET

After-Market: $46.38 +0.02 (0.04%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.68%
2Buy17.55%
3Hold9.21%
4Sell4.93%
5Strong Sell2.36%
S&P50010.96%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

C Value C Growth C Momentum C VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 33% (83 out of 251)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Here's Why You Should Add QIAGEN (QGEN) to Your Portfolio

by Zacks Equity Research

Investors continue to be optimistic about QIAGEN (QGEN) on robust segmental and geographical growth.

Orthofix JuniOrtho Plating System Gets Regulatory Clearances

by Zacks Equity Research

Orthofix (OFIX) rides high on dual regulatory clearances for its deformity correction system, thus solidifying its pediatric orthopedics portfolio.

Amedisys Rides on Coronavirus-Led Business Amid Cost Woes

by Zacks Equity Research

Amedisys (AMED) while seeing a drop in MIS visits is experiencing steady recovery in referral volumes.

Quest Diagnostics Gets EUA for Coronavirus Sample Pool Testing

by Zacks Equity Research

Quest Diagnostics (DGX) is riding high on a slew of EUAs for the expanded use of its self-collection molecular diagnostic kit on different platforms.

Rising Coronavirus Cases Spark Lockdown Fears: 5 Defensive Picks

by Zacks Equity Research

Given the current coronavirus scenario, investors can invest in defensive stocks that can return well even during phases of market volatility

Medtronic Banks on Ventilator Sales Amid Coronavirus Crisis

by Zacks Equity Research

Medtronic (MDT) is currently focusing on the geographical diversification of its businesses, apart from product innovation. Also, it demonstrates a strong solvency position.

Integra Reports Organic Sales Drop in Preliminary Q2 Results

by Zacks Equity Research

Integra (IART) projects a severe impact on revenues due to the coronavirus-led economic crisis despite sequential improvement in monthly sales performance throughout the quarter.

Zacks.com featured highlights include: Laboratory Corporation of America, SpartanNash Company, B&G Foods, QIAGEN and Rent-A-Center

by Zacks Equity Research

Zacks.com featured highlights include: Laboratory Corporation of America, SpartanNash Company, B&G Foods, QIAGEN and Rent-A-Center

5 Stocks Trading Near 52-Week High That Can Scale Higher

by Zacks Equity Research

Investors target stocks that display a bullish run. Stocks seeing price strength have a high chance of carrying the momentum forward.

Henry Schein Banks on Dental Consumable Amid Coronavirus Woes

by Zacks Equity Research

Henry Schein (HSIC) seems upbeat about its dental technology business, Henry Schein One.

Henry Schein Medical to Expand in Telemedicine With VisualDx

by Zacks Equity Research

Henry Schein's (HSIC) VisualDx system to be integrated with Medpod's technology infrastructure for improved patient outcome.

QIAGEN (QGEN) Reports Encouraging Preliminary Q2 Results

by Zacks Equity Research

Preliminary net revenues for second-quarter 2020 improved 18-19% at CER.

Hologic Expands Product Portfolio With New Ultrasound System

by Zacks Equity Research

Hologic's (HOLX) latest cart-based ultrasound system enhances efficiency and accuracy to better meet the requirements of breast imagers and optimize patient care.

Bio-Rad (BIO) Banks on Coronavirus PCR Tests Amid Cost Woes

by Zacks Equity Research

Bio-Rad (BIO) rides on the FDA's emergency use authorization EUA for the Droplet Digital PCR COVID-19 test kit.

Medtronic Launches User-Friendly Insulin Infusion Set in US

by Zacks Equity Research

Medtronic's (MDT) MiniMed Mio Advance infusion set, is aimed at providing optimal user experience to insulin pump-using diabetic patients.

LabCorp Launches At-Home Coronavirus Test Collection Kit

by Zacks Equity Research

LabCorp (LH) claims this to be the first digital COVID-19 service that physicians can use to remotely diagnose patients before any surgery or procedure.

Myriad Genetics, OptraHEALTH Partner to Offer Cancer Knowledge

by Zacks Equity Research

Myriad Genetics (MYGN) collaborates with OptraHEALTH to provide an AI-powered cognitive ChatBOT to serve as a genetic health knowledge platform to prospective hereditary cancer patients.

Align Technology's Rollouts Aid Amid Procedural Deferrals

by Zacks Equity Research

Align Technology's (ALGN) new virtual solutions ensure continuity of care amid pandemic.

Thermo Fisher Stock Rises on Solid Q2 Growth Expectation

by Zacks Equity Research

Thermo Fisher (TMO) provides encouraging Q2 guidance for organic growth.

IDEXX Gains on Diagnostics Revenues, New Coronavirus Tests

by Zacks Equity Research

IDEXX's (IDXX) human health business, OPTI Medical Systems' newly-developed PCR laboratory test kit named OPTI SARS-CoV-2 RNA RT-PCR gains market acceptance.

Boston Scientific's (BSX) ICM System Receives FDA Approval

by Zacks Equity Research

Boston Scientific's (BSX) new ICM System gets the FDA's nod, thus paving way for better detection and treatment of arrhythmias.

Trina Mukherjee headshot

3 MedTech Stocks to Buy Amid Intensifying Coronavirus Fears

by Trina Mukherjee

Let's keep a watch on three stocks that have shown tremendous promise amid the pandemic.

Myriad Genetics Unveils New Home DNA Sample Collection Kit

by Zacks Equity Research

Myriad Genetics' (MYGN) home DNA sample collection test kit for its GeneSight Psychotropic test enables physicians to remotely provide treatment options to patients with mental health issues.

Manaswita Ghosh Dutta headshot

3 AI Healthcare Stocks to Ride Out the Coronavirus Resurgence

by Manaswita Ghosh Dutta

Efficient use of data by artificially intelligent applications has put into the spotlight their urgent need in the healthcare domain.

QIAGEN's (QGEN) Selloff Deal With Thermo Fisher Progresses

by Zacks Equity Research

QIAGEN's (QGEN) acquisition deal with Thermo Fisher receives approval from QIAGEN shareholders.